ClearSky Medical Diagnostics and Shanghai Accurature Diagnostics Co Ltd have entered into a strategic cooperation agreement related to PD-Monitor, a medical device using ClearSky’s proprietary AI technology to assist the diagnosis and measurements of neurodegenerative diseases, such as Parkinson’s.
- Artificial intelligence and wearable technology invented in UK is helping to diagnose and manage Parkinson's in China
- China has the largest number of Parkinson's patients globally (more than half of the world’s Parkinson's patients are in the country)
- ClearSky MD founded by York University Professor Stephen Smith following his appointment as a Royal Academy of Engineering Enterprise Fellow
SHANGHAI, CHINA & YORK, UK: 9 December 2021
ClearSky Medical Diagnostics (‘ClearSky’) and Shanghai Accurature Diagnostics Co Ltd have entered into a strategic cooperation agreement related to PD-Monitor, a medical device using ClearSky’s proprietary AI technology to assist the diagnosis and measurements of neurodegenerative diseases, such as Parkinson’s.
As an active national player specialised in providing diagnostic and care solutions for mental health and neurologic conditions, Shanghai Accurature Diagnostics will be responsible for incubating and commercialising PD-Monitor in China. Following the agreement, ClearSky will continue to drive commercialisation in other parts of the world while focusing on continuous product development.
As a result of a surge in its aging population, it is estimated that China will have nearly half of the world’s Parkinson’s disease population by 2030. This collaboration will not only accelerate the availability of cutting-edge technology to both patients and healthcare professionals in China, but also has the potential to set an example or even transform how early detection and triage of patients at risk of Parkinson’s can be achieved and improved with the help of digital health.
“As a company focused on research and development (R&D), we’re delighted to enter into a commercial agreement with Shanghai Accurature Diagnostics to tackle a huge market such as China,” said Professor Stephen Smith, Founder of ClearSky. “At the same time the arrangement enables us to focus on continuous product development work, from user interface improvement of our existing products to covering exciting new territories, such as dementia.”
Jackie Ho, CEO and founder of Shanghai Accurature Diagnostics, said: “Accurature has the vision to become the leader in China for the provision of novel diagnostic tools and services for healthcare professionals, helping them to make better decisions when it comes to medication for their patients. Therefore, it is an excellent match that Accurature and ClearSky will work together to introduce an AI-based diagnostic device for Parkinson’s disease in China.
“PD-Monitor is the first product in this strategic partnership, and we are both excited about the potential of further collaboration given ClearSky’s expertise in applying machine learning in health.” [ends]
About ClearSky
ClearSky Medical Diagnostics was established in 2013 as a spinout company from the University of York’s Department of Electronics, established by co-founder and director Professor Stephen Smith. The company specialises in developing medical devices for the diagnosis and monitoring of Parkinson’s, Alzheimer’s and a range of other neurodegenerative conditions based on unique biologically-inspired computer algorithms.
www.clearskymd.com
Twitter: @clearskymd, LinkedIn: www.linkedin.com/company/clearsky-medical-diagnostics
About Shanghai Accurature Diagnostics
Shanghai Accurature Diagnostics Co., Ltd. is a subsidiary of Shanghai Conlighti Medical Laboratory Co., Ltd., an end-to-end solution provider dedicated in the research and development, production and sales of In-Vitro Diagnostic products and clinical diagnostic services with a strong focus on mental and neurological disorders. Shanghai Accurature Diagnostics’ GMP manufacturing facility is in Shanghai Bay (Jinshan) District with an area of 65 acres producing IVD devices including instruments and reagents. In 2016, Conlight Medical launched the first genetic testing service for psychiatric drugs, and it has become the largest psychiatric drug genome database in China.At the same time, Conlight Medical has completed nearly 100 million yuan of Pre-B round of financing this year and is moving steadily towards the capital market.
www.accurature.com
Accurature Contact:
Jackie Ho
CEO and founder, Shanghai Accurature Diagnostics
info@accurature.com, +86 (21) 64338133
ClearSky Contact:
Professor Stephen L. Smith
Co-founder and Director, ClearSky Medical Diagnostics
